John Lettieri to Humans
This is a "connection" page, showing publications John Lettieri has written about Humans.
Connection Strength
0.053
-
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Cancer Chemother Pharmacol. 2018 01; 81(1):195-206.
Score: 0.022
-
Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose. J Clin Pharmacol. 2012 Aug; 52(8):1240-7.
Score: 0.015
-
Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study. J Clin Pharmacol. 2019 05; 59(5):654-667.
Score: 0.006
-
No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. Thyroid. 2017 09; 27(9):1118-1127.
Score: 0.006
-
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May; 57(5):685-92.
Score: 0.002
-
Optimizing wound healing in the face after laser abrasion. J Am Acad Dermatol. 2002 Mar; 46(3):399-407.
Score: 0.002